Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GoodRx Holdings (GDRX)
NASDAQ:GDRX
Holding GDRX?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.1Last Year’s EPS
$0.08Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -24.39%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there are significant gains in adjusted EBITDA and the pharma manufacturer solutions segment, challenges in the retail pharmacy environment and its impact on prescription transaction revenue remain a concern.Company Guidance
During the GoodRx Q3 2024 earnings call, the company provided guidance and discussed various metrics, highlighting a 21% year-over-year growth in adjusted EBITDA. The company anticipates revenue for Q4 to be approximately $200 million, with full-year revenue just under $795 million, reflecting around 6% year-over-year growth. GoodRx projects pharma manufacturer solutions to deliver about 20% year-over-year top-line growth in Q4, while acknowledging choppiness in the retail pharmacy environment affecting prescription transactions revenue. The company has direct contracts with 8 of their top 10 retailers, covering over 30% of their volume through hybrid and direct contracts. Looking ahead to 2025, GoodRx expects single-digit percentage revenue growth with adjusted EBITDA margins continuing to rise, driven by clear momentum in pharma manufacturer solutions and ongoing adjustments in the retail landscape.Adjusted EBITDA Growth
Adjusted EBITDA grew by 21.5% year-over-year, indicating strong financial performance. The adjusted EBITDA margin also increased by 520 basis points, showing improved operational efficiency.
Pharma Manufacturer Solutions Expansion
Pharma manufacturer solutions revenue increased by 77% year-over-year. The company expects this segment to achieve about 20% year-over-year top-line growth in the fourth quarter.
Increased Consumer Engagement
Monthly active consumers increased by 7%, showing growth in user engagement.
Strong Cash Position
The company ended the quarter with $423.8 million in cash and cash equivalents, maintaining a robust balance sheet.
---
GDRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GDRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $6.11 | $5.04 | -17.51% |
| Aug 08, 2024 | $8.61 | $7.01 | -18.58% |
| May 09, 2024 | $7.61 | $6.93 | -8.94% |
| Feb 29, 2024 | $6.47 | $7.79 | +20.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GoodRx Holdings (GDRX) report earnings?
GoodRx Holdings (GDRX) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is GoodRx Holdings (GDRX) earnings time?
GoodRx Holdings (GDRX) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GDRX EPS forecast?
GDRX EPS forecast for the fiscal quarter 2024 (Q4) is $0.1.
---
